Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis

Figure 4 Forest plots of common adverse reactions. Ghosh 2003¹: 6 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003²: 3 mg/kg natalizumab at 0 and 4 wk; Ghosh 2003³: 3 mg/kg natalizumab at 0 wk. Feagan 2008¹: 2 mg/kg vedolizumab at 0 and 4 wk; Feagan 2008²: 0.5 mg/kg vedolizumab at 0 and 4 wk.